Clinical disclaimer: This article is educational and does not constitute personal medical advice. If you take medication affected by weight change, or have type 2 diabetes, involve your clinician before making any changes. Never stop medication abruptly without clinical supervision.

Why target weight is not the end of the clinical conversation

Reaching target weight on Mounjaro or Wegovy is a significant clinical achievement. It is also the point at which many patients — and their prescribers — conclude the treatment should end. The logic is intuitive: the goal was reached, so the treatment is complete. The problem is that this logic treats GLP-1 medication like antibiotics for an infection, rather than like antihypertensives for blood pressure. The former treats and resolves; the latter manages an ongoing condition.

The evidence is consistent: stopping GLP-1 medication after reaching target weight leads to regain in most patients. How much, and how quickly, varies. That it happens is predictable enough to plan for.

What SURMOUNT-4 and STEP 1 extension show

Both trials captured what happens after successful weight loss when medication is stopped. SURMOUNT-4 showed participants regaining approximately 14% body weight over 52 weeks after stopping tirzepatide; by week 88, total weight loss from baseline was 9.9% in those who stopped versus 25.3% in those who continued. [1] STEP 1 extension showed two-thirds of semaglutide-induced weight loss regained within one year of stopping. [2] These participants had reached substantial weight loss before stopping — they met the equivalent of a clinical target. They still regained.

The biological reason: setpoint and adaptation

Reaching target weight does not reset the biological setpoint that produced excess weight in the first place. The hypothalamic programming that drove appetite, the hormonal environment that resisted weight loss, and the adaptive metabolic changes that occurred during weight loss all persist after target weight is reached. GLP-1 medication was managing these — not curing them. Stopping at target weight removes the management without removing the underlying biology. [3]

Who can stop and maintain successfully?

A minority of patients do maintain well after stopping at target weight. The characteristics consistently associated with this outcome: substantial lifestyle change during treatment — specifically consistent resistance training and protein-anchored eating that have become genuine habits, not compliance behaviours. Duration of treatment — patients who have been at target weight for six or more months before stopping tend to do better than those who stop at the first target reading. And underlying drivers addressed: patients whose weight was significantly driven by reversible factors (poor sleep, high alcohol intake, sedentary occupation now changed) do better than those for whom obesity is predominantly constitutional or genetic.

The right conversation to have before stopping

Before stopping GLP-1 medication at target weight, ask: have I genuinely built the structural foundations — resistance training, protein, consistent monitoring — or has the medication been doing the work? If I regain 5 kg in the next three months, what is my plan? Do my blood pressure or diabetes medications need reviewing now that I am at this weight? What is the threshold at which I would restart?

These questions do not require pessimism about success. They require planning for the most likely clinical scenario, which is some degree of regain. A GLP-1 Exit Strategy Review is designed for exactly this moment — not as a concession to failure, but as the clinical step that most improves the odds of a durable outcome.

Considering maintenance dosing instead of stopping

For patients who have reached target weight and want to reduce rather than eliminate medication, a lower maintenance dose may be worth discussing with their clinician. The evidence for dose-reduced maintenance is limited but the pharmacological rationale is reasonable. See Mounjaro maintenance dose for the evidence detail.

FAQ

Should I stop Mounjaro when I reach my target weight?
Not necessarily. Reaching target weight means the treatment has worked, not that it is complete. The biology that produced excess weight — hypothalamic setpoint, hormonal environment, adaptive metabolism — persists after target weight is reached. Most patients who stop at target weight regain significantly within one year.
Can I maintain my weight without GLP-1 medication after reaching target?
Some people do, particularly those who have built consistent resistance training and protein-anchored eating habits during treatment, and whose weight was driven by reversible factors. The evidence suggests most people regain meaningfully after stopping. Structural preparation before stopping changes the individual outcome.
What is the best time to stop GLP-1 medication?
If stopping at target weight, waiting until you have been at that weight for at least three to six months — and have the structural foundations (resistance training, protein, monitoring) genuinely in place — gives the best odds of maintenance. Stopping at the first target reading, without these foundations, carries the highest regain risk.
How much weight will I regain after stopping Mounjaro at target weight?
Individual variation is large. The trials show mean regain of approximately 14% body weight (tirzepatide, SURMOUNT-4) and two-thirds of lost weight (semaglutide, STEP 1 extension) within one year. With structural foundations in place, individual outcomes are often meaningfully better than these population means.
Should I consider a lower dose instead of stopping completely?
Possibly. A lower maintenance dose may preserve some benefit at reduced cost and side-effect burden. This is worth discussing with your prescribing clinician. There is no strong trial evidence that dose-reduced maintenance outperforms full-dose continuation, but the pharmacological logic is sound. See Mounjaro maintenance dose for detail.

References

  1. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction: SURMOUNT-4. JAMA. 2024.
  2. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP 1 extension. Diabetes Obes Metab. 2022.
  3. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011.